June, 2025

article thumbnail

Why CVS, Express Scripts Are Suing Over the Arkansas PBM Law

MedCity News

Arkansas became the first state to pass a law banning pharmacy benefit managers from owning pharmacies, aiming to curb their market power and reduce drug costs. But major PBMs like CVS and Express Scripts are suing, claiming the law is unconstitutional. The post Why CVS, Express Scripts Are Suing Over the Arkansas PBM Law appeared first on MedCity News.

article thumbnail

From Public to Private: Do Laid-Off FDA and CDC Employees Have the Skills Pharma and Biotech Need?

World of DTC Marketing

With reports of budget constraints and layoffs hitting federal agencies like the FDA and CDC, many talented public health professionals are suddenly finding themselves out of work. As they look to the private sector—particularly the pharmaceutical and biotech industries—the question arises: do they possess the right business skills to make a successful transition ?

Pharma 244
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care.

Patients 221
article thumbnail

FDA’s Elsa AI is here, and the industry has questions

PharmaVoice

The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.

260
260
article thumbnail

State of AI in Sales & Marketing 2025

AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.

article thumbnail

The Best Medical Sales Jobs You Should Know

Evolve Your Success

Why Medical Sales Is a Career Worth Exploring Medical sales isn’t just a job, it’s one of the most dynamic, financially rewarding, and purpose-driven careers in healthcare. Whether you’re a recent grad, a healthcare provider ready to pivot, or a seasoned sales pro looking for a challenge, there’s a role for you. In this bold new era of healthcare and medical sales, demand is high, innovation is constant, and opportunities are everywhere. 1.

More Trending

article thumbnail

What Will Be Healthcare’s Next Big AI Use Case Following Ambient Scribes?

MedCity News

Over the past couple of years, ambient scribes have earned widespread adoption among health systems. While there’s excitement around other categories like AI agents and denials management, no other AI use case has achieved ambient scribes’ level of traction, noted Daniel Yang, Kaiser Permanente’s vice president of AI and emerging technologies.

article thumbnail

Sorry, Bernie, but DTC Ads Inform and Educate—They Don’t Drive Unnecessary Prescriptions

World of DTC Marketing

Direct-to-consumer (DTC) pharmaceutical advertising is often caught in the crossfire of political debates. Senator Bernie Sanders, among other critics, has repeatedly asserted that DTC ads inflate healthcare costs by driving unnecessary prescriptions. But is this perspective supported by evidence? The reality tells a different story. DTC Ads Empower Patients Through Education Contrary to popular critiques, DTC advertisements serve as a crucial educational tool, enabling patients to engage more p

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

The FDA has blessed Merck’s clesrovimab to protect against lower respiratory tract disease related to respiratory syncytial virus in newborns and infants. The monoclonal antibody, which will be known commercially as Enflonsia, will challenge Sanofi and AstraZeneca’s blockbuster Beyfortus.

FDA 198
article thumbnail

The biggest obesity deals of 2025 so far

PharmaVoice

Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve

Pharma 147
article thumbnail

The Intersection of AI and Sales: Personalization Without Compromise

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

article thumbnail

Medical Sales: A Physical Therapist’s Burnout to Breakthrough

Evolve Your Success

Want to Win in Medical Sales? Master These Skills First This episode is everything you need to transition from healthcare to medical sales. April Hoffman, a former physical therapist turned medical sales leader, shares how she used her clinical background to break into the industry and thrive. Her story proves that your healthcare experience is not just relevant, its a powerful asset.

article thumbnail

Argenx presents new efgartigimod data at EULAR 2025

PharmaTimes

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Argenx presents new efgartigimod data at EULAR 2025 by John Pinching | 11th Jun 2025 | News Rheumatology studies show promising results for Sjogren’s disease Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025.

article thumbnail

Lucet to Acquire Home Care Company Emcara Health

MedCity News

Lucet, a behavioral health company, is acquiring home care company Emcara Health to offer integrated care models. The post Lucet to Acquire Home Care Company Emcara Health appeared first on MedCity News.

264
264
article thumbnail

It’s Time to Admit: In an Era of High Distrust, Pharma DTC TV Ads Are Ineffective

World of DTC Marketing

For decades, pharma companies have relied on direct-to-consumer (DTC) television ads to build awareness and drive demand for prescription drugs. However, as the healthcare landscape continues to evolve—and trust in institutions declines—it’s time for the industry to confront a hard truth: DTC TV ads are no longer as effective as they once were. They may be increasingly out of step with how patients make healthcare decisions today.

Pharma 222
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

The drug is the first triple-combo pill for the initial treatment of hypertension in the U.S.

225
225
article thumbnail

The former Wall Street analyst shaping Novartis’ big-picture strategy

PharmaVoice

Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

130
130
article thumbnail

Streeting pledges clinical trial signups in the NHS App

pharmaphorum

Millions of people in the UK will be given the opportunity to take part in clinical trials via the NHS App

96
article thumbnail

AI-powered orchestration: Bringing the benefits to personalized therapy

Pharmaceutical Technology

Supply chains for a new generation of therapies are complex, costly, and require meticulous management to ensure patient safety and regulatory compliance. AI can transform cell and gene therapy (CGT) orchestration by automating manual processes, improving productivity, enhancing supply chain visibility and improving scalability.

Safety 102
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

How Technology Is Personalizing Healthcare in 2025

MedCity News

Modern technology with AI at its center is creating unique opportunities to approach healthcare challenges in ways that weren’t possible just a few years back. The post How Technology Is Personalizing Healthcare in 2025 appeared first on MedCity News.

article thumbnail

No! DTC Ads Should Not Be Banned

World of DTC Marketing

In June 2025, Senators Bernie Sanders and Angus King introduced legislation to ban direct-to-consumer (DTC) pharmaceutical advertising across all primary media channels, including TV, radio, print, digital platforms, and social media. Their argument? DTC ads are misleading, overly influential, and contribute to rising healthcare costs. The bill reflects a long-standing concern that pharmaceutical companies are too aggressive in marketing prescription drugs to the public, often at the expense of

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

After questioning the benefits of checkpoint inhibitors in stomach cancer cases without PD-L1 expression, the FDA has moved to restrict the use of Merck's and Bristol Myers Squibb's immunotherapies in those patients.

FDA 237
article thumbnail

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve

Pharma 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Caris swells its planned IPO, seeking $5.7bn valuation

pharmaphorum

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Oncology -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -Wh

Media 89
article thumbnail

What Is Pharmaceutical Marketing and How Is It Evolving in 2025

Pharma Marketing Network

Pharmaceutical marketing has always been a dynamic force within the healthcare ecosystem. In 2025, the pace of change is faster than ever, driven by innovations in digital technology, new regulatory landscapes, and shifting expectations among healthcare providers and patients alike. So what exactly is pharmaceutical marketing today, and how is it adapting to meet tomorrow’s challenges?

article thumbnail

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

MedCity News

AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.

Pharma 235
article thumbnail

Why MDs Should Not Lead Medical Affairs For Best Results

World of DTC Marketing

In the pharma industry, it’s almost reflexive to tap an MD for the role of Vice President of Medical Affairs. After all, Medical Affairs serves as the bridge between clinical research, regulatory compliance, marketing, and real-world evidence — all areas where deep medical knowledge is a valuable asset. But here’s the truth few want to say out loud: appointing an MD as head of Medical Affairs isn’t always the best move.

Leads 208
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

In late April, when Sanofi revealed that it was selling a controlling stake in its consumer health business Opella for 10 billion euros, chief financial officer Francois Roger said that the French drugmaker would “explore external growth opportunities for bolt-on acquisitions.” Just five weeks later, Sanofi has made a deal few would describe as “bolt-on,” as it has bought out Blueprint Medicines for $9.5 billion.

Medicine 204
article thumbnail

Sanofi to acquire Blueprint for up to $9.5B

PharmaVoice

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

Pharma 130
article thumbnail

Genentech's Bittenbender named board chair at BIO

pharmaphorum

Genentech's Fritz Bittenbender becomes chair of the Biotechnology Innovation Organization at a challenging time for the sector.

90